Latest Insider Transactions at Terns Pharmaceuticals, Inc. (TERN)
This section provides a real-time view of insider transactions for Terns Pharmaceuticals, Inc. (TERN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Terns Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Terns Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 31
2022
|
Mark J. Vignola Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
7,656
+50.0%
|
$7,656
$1.47 P/Share
|
|
May 31
2022
|
Seokho Bryan Yoon COO and General Counsel |
BUY
Open market or private purchase
|
Direct |
7,656
+50.0%
|
$7,656
$1.47 P/Share
|
|
Feb 09
2021
|
Vivo Capital Viii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
475,000
+19.89%
|
$8,075,000
$17.0 P/Share
|
|
Feb 09
2021
|
Vivo Capital Viii, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,200,133
+50.0%
|
-
|
|
Feb 09
2021
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
475,000
+11.13%
|
$8,075,000
$17.0 P/Share
|
|
Feb 09
2021
|
Carl L Gordon Director |
BUY
Conversion of derivative security
|
Indirect |
3,316,204
+50.0%
|
-
|
|
Feb 09
2021
|
Lav Biosciences Fund V, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
4,781,566
+50.0%
|
-
|
|
Feb 09
2021
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
475,000
+11.13%
|
$8,075,000
$17.0 P/Share
|
|
Feb 09
2021
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
3,316,204
+50.0%
|
-
|
|
Feb 09
2021
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
665,000
+21.82%
|
$11,305,000
$17.0 P/Share
|
|
Feb 09
2021
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,717,033
+50.0%
|
-
|